TrialJCO precision oncology2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Haider Mahdi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this papertrialcites it